Glycogen synthase kinase (GSK)-3β levels and activity in a neurodevelopmental rat model of schizophrenia
- 14 March 2003
- journal article
- Published by Elsevier in Developmental Brain Research
- Vol. 141 (1-2) , 33-37
- https://doi.org/10.1016/s0165-3806(02)00639-9
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Somatic mutations ofWNT/wingless signaling pathway components in primitive neuroectodermal tumorsInternational Journal of Cancer, 2001
- Up-Regulation of WNT-4 Signaling and Dosage-Sensitive Sex Reversal in HumansAmerican Journal of Human Genetics, 2001
- Glycogen synthase kinase-3β immunoreactivity is reduced in the prefrontal cortex in schizophreniaNeuroscience Letters, 2001
- Differential DNA damage in response to the neonatal and adult excitotoxic hippocampal lesion in ratsEuropean Journal of Neuroscience, 2000
- Low GSK-3β Immunoreactivity in Postmortem Frontal Cortex of Schizophrenic PatientsAmerican Journal of Psychiatry, 2000
- Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neuronsProceedings of the National Academy of Sciences, 1999
- Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysisPsychopharmacology, 1999
- Regionally Specific Neuronal Pathology in Untreated Patients with Schizophrenia: A Proton Magnetic Resonance Spectroscopic Imaging StudyBiological Psychiatry, 1998
- A molecular mechanism for the effect of lithium on development.Proceedings of the National Academy of Sciences, 1996
- Gene Expression for Glutamic Acid Decarboxylase Is Reduced Without Loss of Neurons in Prefrontal Cortex of SchizophrenicsArchives of General Psychiatry, 1995